Drug interactions
Encorafenib + Ruxolitinib
Severity: Moderate
Encorafenib and Ruxolitinib: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Encorafenib both inhibits and induces CYP3A4, so ruxolitinib exposure may increase or decrease unpredictably. This may result in toxicity such as cytopenias or reduced efficacy.
What this interaction means in plain words
Encorafenib and Ruxolitinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Encorafenib belongs to Oncology; Ruxolitinib belongs to Oncology.
Why it happens
Encorafenib exerts mixed CYP3A4 inhibition and induction on ruxolitinib metabolism.
What to do
Monitor blood counts and clinical response, and adjust ruxolitinib dose according to tolerability and efficacy.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Encorafenib and Ruxolitinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Ruxolitinib
Other interactions of Encorafenib
Frequently asked questions
Can I take Encorafenib with Ruxolitinib?
MediHelp rates the interaction as moderate. Encorafenib and Ruxolitinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Encorafenib both inhibits and induces CYP3A4, so ruxolitinib exposure may increase or decrease unpredictably. This may result in toxicity such as cytopenias or reduced efficacy.
How serious is the interaction between Encorafenib and Ruxolitinib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood counts and clinical response, and adjust ruxolitinib dose according to tolerability and efficacy.
What other medicines interact with Ruxolitinib?
MediHelp also lists interactions of Ruxolitinib with, for example, Atazanavir, Ceritinib, Chloramphenicol. The full list is on the Ruxolitinib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
